Crucial US Panel to Cast Ballots on Altering Newborn Hepatitis B Vaccine Recommendation
Following a postponement and an unusually contentious gathering, a government vaccine expert group was scheduled to decide on Friday concerning altering the long-held guideline that every infant be inoculated against hepatitis B.
Fiery Exchange and a Delayed Ballot
The first day of the conference on Thursday was marked by heated debate over curbing eligibility to the hepatitis B vaccine for newborns and a resolution to postpone the decision by a day to provide committee members extra time to examine the language. The group, which counsels the Centers for Disease Control and Prevention on vaccination protocols, had put off the vote twice in the past.
“Is there any specific evidence of harm of giving this immunization before 30 days? Or is this speculation?” inquired one adviser.
In answer, another member stated, “There is inadequate data about the prolonged hazard.”
Existing Recommendations and Likely Ramifications
The vaccine is presently advised for all infants within 24 hours of being born to halt contraction of hepatitis B, which can result in serious liver damage. It has been administered to 1.4 billion people for more than three decades.
The Atlanta conference presented no new evidence of harms caused by the vaccine. Specialists note any modification to the existing hepatitis B vaccine regimen could have major and extensive consequences for childhood health in the United States.
Committee Makeup and Recent Changes
The consultative group can only offer guidance to the leader of the CDC. The group's roster has experienced alterations in recent days, with the statement that the committee’s most recent chair would leave for an agency job and be substituted with a heart specialist who has been skeptical about other immunizations.
The board includes a number of vaccination critics who are in agreement with a aim to revamp – and possibly, in some cases, eliminate – traditional immunization guidelines.